Detalhe da pesquisa
1.
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.
Lancet Oncol
; 24(9): 1002-1017, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657460
2.
miRNA-Seq Tissue Diagnostic Signature: A Novel Model for NSCLC Subtyping.
Int J Mol Sci
; 24(17)2023 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37686123
3.
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Int J Mol Sci
; 22(2)2021 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33435596
4.
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Lancet Oncol
; 20(12): 1702-1709, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31628016
5.
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Oncologist
; 24(6): e251-e259, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30139835
6.
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Lancet Oncol
; 16(7): 763-74, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26045340
7.
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Lancet Oncol
; 16(3): 328-37, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25701171
8.
Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer.
Anticancer Drugs
; 26(10): 1061-8, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26295868
9.
The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies.
Contemp Oncol (Pozn)
; 19(4): 313-22, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26557780
10.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(1): 59-68, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24331154
11.
C-MET inhibitors in the treatment of lung cancer.
Curr Treat Options Oncol
; 15(4): 670-82, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25266653
12.
[The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations]. / Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka pluca i zlosliwego miedzybloniaka oplucnej: uaktualnione zalecenia ekspertów.
Pneumonol Alergol Pol
; 82(2): 133-49, 2014.
Artigo
em Polonês
| MEDLINE | ID: mdl-24615197
13.
Actual status of therapeutic vaccination in non-small cell lung cancer.
Contemp Oncol (Pozn)
; 18(2): 77-84, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24966788
14.
Head-to-Head Comparison of [18F]PSMA-1007 and [18F]FDG PET/CT in Patients with Triple-Negative Breast Cancer.
Cancers (Basel)
; 16(3)2024 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38339419
15.
Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.
Onco Targets Ther
; 17: 267-280, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38567193
16.
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
JNCI Cancer Spectr
; 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627238
17.
The analysis of ALK gene rearrangement by fluorescence in situ hybridization in non-small cell lung cancer patients.
Contemp Oncol (Pozn)
; 17(6): 484-92, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24592134
18.
Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Lancet Oncol
; 13(3): 292-9, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22336221
19.
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Lancet Oncol
; 13(1): 33-42, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22056021
20.
A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives.
Cells
; 12(6)2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36980246